Objective To observe the efficacy of anti - HBV DNA medicine and different combina-tion. Methods 170 ASC CHB patients were categorized into two groups( group Ⅰ, hays 65 patients, they were randomised to receive Famcilovir combine with Interferon- γ; group Ⅱ , hays 105 patients they were randomised to receive Famcilovir combine with Thymopentin), the controls treat by Interferon - a2b. Re-stilt 53.3 % of the group Ⅰ and 38.3 % of the group Ⅱ had undetectable serum HBV DNA, compared with 28.6% in the control group: the people diminition 10^2 coples/ml,38.8% of whom are in the group Ⅰ ,49.5% whom are in the group Ⅱ ,compared with 28.6% in control group(P < 0.025) ;After treat-ment, they also go down more obviously in HBeAg HbsAg and the group Ⅰ is better than the group Ⅱ .Conclusion Conbination of two different medicine is a useful method, and it may indicate that much time is neccssary to receive anti- HBV DNA patients, especially to theose accept immune treatment.
展开▼
